Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings

Starting soon

Conditions studied: HGSOC

In brief

* To compare DHODH protein expression in HGSC tissues from patients undergoing Primary Debulking Surgery (PDS - Chemo-naive) versus Interval Debulking Surgery (IDS - Post-NACT). * To evaluate the association between DHODH expression and the degree of chemotherapy response (using the Chemotherapy Response Score - CRS for NACT cases). * To determine the prognostic value of DHODH expression in predicting Platinum-Free Interval (PFI) ,Progression -Free Survival (PFS) and Overall Survival (OS) across both groups.

Key facts

Study ID

NCT07366242

Run by

Heba Ahmed Mohamed

People needed

72

Starts

2026-06-01

Expected to finish

2027-07-01

Last updated by the study team

2026-01-26

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed high-grade serous ovarian carcinoma
• Availability of adequate FFPE tumor tissue
• Known treatment modality (PDS or IDS)
• Available clinical follow-up including platinum-free interval and survival data

You may not qualify if…

• Non-serous histological subtypes
• Low-grade serous carcinoma
• Inadequate tissue for immunohistochemistry
• Missing clinical or follow-up data

Where it is running

• Assiut University — Asyut, Egypt

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.